bepridil has been researched along with Electrocardiogram QT Prolonged in 14 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 9.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 9.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 9.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "Bepridil has complex pharmacokinetic (PK) properties with large interindividual differences in plasma concentrations." | 6.78 | Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. ( Hagiwara, N; Hashiguchi, M; Naganuma, M; Shiga, T; Suzuki, A, 2013) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 5.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 5.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 5.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "Bepridil prolongs the QT interval and can induce torsade de pointes." | 4.02 | Relationship between serum bepridil concentration and corrected QT interval. ( Hayakawa, N; Hosomi, K; Kawabata, A; Kusano, K; Matsui, K; Mukai, Y; Nakamura, T; Sakakura, K; Takada, M; Terakawa, N; Wada, K; Yokoyama, S, 2021) |
| "Bepridil has complex pharmacokinetic (PK) properties with large interindividual differences in plasma concentrations." | 2.78 | Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. ( Hagiwara, N; Hashiguchi, M; Naganuma, M; Shiga, T; Suzuki, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Matsui, K | 1 |
| Mukai, Y | 1 |
| Sakakura, K | 1 |
| Wada, K | 1 |
| Nakamura, T | 1 |
| Kawabata, A | 1 |
| Terakawa, N | 1 |
| Hayakawa, N | 1 |
| Kusano, K | 1 |
| Hosomi, K | 1 |
| Yokoyama, S | 1 |
| Takada, M | 1 |
| Gravel, AE | 1 |
| Arnold, AA | 1 |
| Dufourc, EJ | 1 |
| Marcotte, I | 1 |
| Shiga, T | 1 |
| Hashiguchi, M | 1 |
| Naganuma, M | 2 |
| Suzuki, A | 1 |
| Hagiwara, N | 1 |
| Sasaoka, S | 1 |
| Matsui, T | 1 |
| Hane, Y | 1 |
| Abe, J | 2 |
| Ueda, N | 1 |
| Motooka, Y | 1 |
| Hatahira, H | 1 |
| Fukuda, A | 1 |
| Hasegawa, S | 1 |
| Kinosada, Y | 1 |
| Nakamura, M | 1 |
| Said, TH | 1 |
| Wilson, LD | 1 |
| Jeyaraj, D | 1 |
| Fossa, AA | 1 |
| Rosenbaum, DS | 1 |
| Kawamura, M | 1 |
| Munetsugu, Y | 1 |
| Tanno, K | 1 |
| Kobayashi, Y | 1 |
| Pareja, K | 1 |
| Chu, E | 1 |
| Dodyk, K | 1 |
| Richter, K | 1 |
| Miller, A | 1 |
| Yoshiga, Y | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Hayano, T | 1 |
| Ueyama, T | 1 |
| Ohmura, M | 1 |
| Itagaki, K | 1 |
| Kimura, M | 1 |
| Matsuzaki, M | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Sasaki, A | 1 |
| Kawano, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Daida, H | 1 |
| Miyaji, K | 1 |
| Tada, H | 1 |
| Fukushima Kusano, K | 1 |
| Hashimoto, T | 1 |
| Kaseno, K | 1 |
| Hiramatsu, S | 1 |
| Tadokoro, K | 1 |
| Naito, S | 1 |
| Nakamura, K | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Ohe, T | 1 |
| Chouabe, C | 1 |
| Drici, MD | 1 |
| Romey, G | 1 |
| Barhanin, J | 1 |
| Lazdunski, M | 1 |
| Viallon, A | 1 |
| Laporte-Simitsidis, S | 1 |
| Pouzet, V | 1 |
| Venet, C | 1 |
| Tardy, B | 1 |
| Zéni, F | 1 |
| Bertrand, JC | 1 |
5 trials available for bepridil and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Area Under Curve; Asian People; Atrial Fibrillation; Bepr | 2013 |
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Car | 2013 |
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Bisoprolol | 2002 |
Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bepridil; Bradycardi | 2006 |
Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Drug Therapy, Combination; Electrocardi | 2007 |
9 other studies available for bepridil and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Relationship between serum bepridil concentration and corrected QT interval.
Topics: Bepridil; Electrocardiography; Humans; Japan; Long QT Syndrome; Retrospective Studies; Torsades de P | 2021 |
An NMR investigation of the structure, function and role of the hERG channel selectivity filter in the long QT syndrome.
Topics: Bepridil; Cetirizine; Dimyristoylphosphatidylcholine; Diphenhydramine; ERG1 Potassium Channel; Ether | 2013 |
Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events.
Topics: Administration, Oral; Aprindine; Bepridil; Databases, Factual; Female; Humans; Long QT Syndrome; Mal | 2016 |
Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Topics: Action Potentials; Animals; Bepridil; Dogs; Dose-Response Relationship, Drug; Electrocardiography; E | 2012 |
Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Topics: Bepridil; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Potass | 2013 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers.
Topics: Animals; Benzimidazoles; Bepridil; Calcium Channel Blockers; Cloning, Molecular; COS Cells; Heart; I | 1998 |
[Bepridil: importance of serum level in treatment surveillance].
Topics: Aged; Aged, 80 and over; Bepridil; Dose-Response Relationship, Drug; Drug Monitoring; Electrocardiog | 2000 |